NasdaqGS:CRNXPharmaceuticals
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress
Crinetics Pharmaceuticals (CRNX) has been in focus after a Goldman Sachs analyst upgrade that followed positive Phase 2 data for atumelnant in congenital adrenal hyperplasia and encouraging early revenue from newly launched Palsonify.
See our latest analysis for Crinetics Pharmaceuticals.
The latest move in Crinetics shares, which closed at US$56.43, comes after a string of updates including the Palsonify launch, positive atumelnant data, and a US$350.1m follow on equity raise. The 30 day...